2020
Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study
Grilo CM, Lydecker JA, Morgan PT, Gueorguieva R. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study. Clinical Therapeutics 2020, 43: 112-122.e1. PMID: 33218742, PMCID: PMC7902424, DOI: 10.1016/j.clinthera.2020.10.010.Peer-Reviewed Original ResearchConceptsBinge-eating disorderEating-disorder psychopathologyPilot RCTTreatment of BEDOutcome time pointDouble-blind treatmentPercentage of patientsControlled Pilot StudyDiscontinuation of medicationTreatment of bingeEvidence-based treatmentsBinge-eating frequencyBupropion combinationAdult patientsAdverse eventsComorbid obesitySecondary outcomesPrimary outcomeAcute effectsFunctional impairmentPlaceboLong-term effectsPatientsMost outcomesObesity
2015
Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety.
O'Malley SS, Corbin WR, Leeman RF, DeMartini KS, Fucito LM, Ikomi J, Romano DM, Wu R, Toll BA, Sher KJ, Gueorguieva R, Kranzler HR. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. The Journal Of Clinical Psychiatry 2015, 76: e207-13. PMID: 25742208, PMCID: PMC4442987, DOI: 10.4088/jcp.13m08934.Peer-Reviewed Original ResearchConceptsHeavy drinking daysBlood alcohol concentrationPercent days abstinentDrinking daysNumber of drinksYoung adultsDays abstinentPercent heavy drinking daysOutpatient research centerSafety of naltrexonePlacebo-controlled studySerious adverse eventsRisk-benefit ratioPercentage of daysAdverse eventsSecondary outcomesPrimary outcomeFrequency of drinkingOpioid antagonistAdult heavy drinkersAlcohol drinkingClinical trialsEvaluable samplesYoung adult heavy drinkersTreatment period
2013
Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response
Gueorguieva R, Wu R, Krystal JH, Donovan D, O'Malley SS. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response. Addictive Behaviors 2013, 38: 2119-2127. PMID: 23435273, PMCID: PMC3595348, DOI: 10.1016/j.addbeh.2013.01.024.Peer-Reviewed Original ResearchConceptsPercent heavy drinking daysAdherence trajectoriesExcellent adherersPercent days abstinentPatient characteristicsMedication adherenceTreatment outcomesMedication adherence trajectoriesPatterns of treatmentHeavy drinking daysPatterns of adherenceExcellent medication adherenceLack of benefitTrajectories of adherenceIntervention main effectsActive medicationAdverse eventsPharmacologic treatmentHigher percent days abstinentTreatment adherenceTreatment modalitiesWorse outcomesTreatment responseDays abstinentDrinking days
2012
A single-day paradigm of self-regulated human cocaine administration
Matuskey D, Pittman B, Chen JI, Wanyiri J, Nadim H, Jatlow P, Gueorguieva R, Potenza MN, Morgan PT, Bhagwagar Z, Malison RT. A single-day paradigm of self-regulated human cocaine administration. Pharmacology Biochemistry And Behavior 2012, 103: 95-101. PMID: 22922558, PMCID: PMC3652339, DOI: 10.1016/j.pbb.2012.08.009.Peer-Reviewed Original Research
2005
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
D’Souza D, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry 2005, 57: 594-608. PMID: 15780846, DOI: 10.1016/j.biopsych.2004.12.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAkathisia, Drug-InducedArousalCognitionDose-Response Relationship, DrugDouble-Blind MethodDronabinolEndocrine SystemFemaleHumansInjections, IntravenousMaleMental RecallMiddle AgedMotor ActivityNeuropsychological TestsPerceptionPsychiatric Status Rating ScalesPsychotic DisordersPsychotropic DrugsSchizophreniaVerbal LearningConceptsSchizophrenia patientsAntipsychotic-treated schizophrenia patientsDelta-9-tetrahydrocannabinol effectsLong-term adverse eventsCognitive deficitsPlacebo-controlled studyDelta-9-THCTransient exacerbationAdverse eventsReceptor dysfunctionEndocrine effectsHealthy subjectsStudy participationPsychotic disordersPlasma prolactinSchizophrenia symptomsPatientsSchizophreniaCognitive effectsPerceptual alterationsDeficitsCannabisSubjectsAkathisiaExacerbationA paradigm to investigate the self-regulation of cocaine administration in humans
Sughondhabirom A, Jain D, Gueorguieva R, Coric V, Berman R, Lynch WJ, Self D, Jatlow P, Malison RT. A paradigm to investigate the self-regulation of cocaine administration in humans. Psychopharmacology 2005, 180: 436-446. PMID: 15726333, DOI: 10.1007/s00213-005-2192-8.Peer-Reviewed Original ResearchConceptsCocaine administrationCocaine infusionsEscalating-dose regimenSignificant adverse eventsEffective pharmacological treatmentFixed ratio 1Dose-response relationshipCocaine-taking behaviorAnalgesia methodsAdverse eventsMeasures of cocainePharmacological treatmentNarcotic analgesicsCocaine doseIntravenous cocaineCocaine addictionLess cocaineDrug accessCocaineCocaine usersTest daySignificant main effectInfusionAdministrationSession duration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply